Duravant Announces Retirement of CEO Mike Kachmer, Names Jill Evanko Successor
17.11.2025 16:13:00 CET | Business Wire | Press Release
Duravant LLC (“Duravant”), a global leader in advanced automation solutions, announced today that Mike Kachmer will retire from his role as Chief Executive Officer after a highly successful tenure with the company. Duravant’s Board of Directors has named Jill Evanko as CEO, joining the company on January 5, 2026. To ensure a seamless transition, Mr. Kachmer will continue to serve as Chairman of Duravant. Mr. Kachmer will also continue to serve on the Board of Directors for Northwestern Memorial Healthcare and The London Clinic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117036720/en/
Mike Kachmer
“It has been a true honor and a humbling experience to lead this incredible company,” said Mr. Kachmer. “I am profoundly grateful to my colleagues within Duravant for their support over the years. Together, we have built an organization with a truly differentiated operating model and culture, one that cultivates collaboration, empowers innovation, and operates with unwavering integrity.”
Jill Evanko joins Duravant from Chart Industries, Inc. (NYSE: GTLS) where she served as President and Chief Executive Officer since 2018. Prior, Ms. Evanko was the Chief Financial Officer of Truck-Lite Co. LLC, and held multiple executive leadership positions at Dover Corporation (NYSE: DOV) and its subsidiaries. Earlier in her career, she held financial and operational roles at Arthur Andersen LLP, Honeywell Corporation and Sony Corporation. Ms. Evanko received a Master of Business Administration degree from The University of Notre Dame and a Bachelor of Science degree in Business Administration from La Salle University. Ms. Evanko also serves as an independent director of the Board of Greif, Inc. (NYSE: GEF, GEF.B)
“It is a privilege to join Duravant and build upon the remarkable foundation established by Mike,” said Jill Evanko. “I’m grateful to him for the strong legacy of excellence he leaves behind, and I’m excited to work with this exceptional team to advance our mission and shape Duravant’s next chapter of success.”
Under Mr. Kachmer’s leadership, Duravant emerged as a prominent player in the industrial automation sector. Mr. Kachmer led the company’s transformation through 30 acquisitions and strategic partnerships and set the company’s vision to expand into new market segments. He also grew Duravant’s global footprint throughout the Americas, Europe, and Asia and strengthened its position in emerging markets with the establishment of sales and service centers in Brazil, Mexico, China, Thailand, and India.
“Mike’s retirement will mark the end of a remarkable career with Duravant. With his vision steering the company, Duravant has delivered unrivaled growth driven by innovation, operational excellence, and a fine-tuned customer focus,” said Jeff Goldfaden, Managing Director and Head of Industrials at Warburg Pincus and member of Duravant’s Board of Directors. “We are looking forward to welcoming Jill as Duravant’s next CEO. Her strategic mindset and extensive leadership experience at best-in-class industrials companies position her to build upon Duravant’s core strengths and lead the company’s future success.”
“On behalf of the Board, I’d like to extend our deep appreciation to Mike for his unwavering commitment and outstanding service to Duravant. His leadership and strategic direction have been instrumental in shaping the company into the high performing organization it is today,” said Wes Bieligk, Partner at Carlyle and member of Duravant’s Board of Directors. “We’re excited to welcome Jill to Duravant. Her deep expertise and accomplishments reflect the same commitment to excellence and collaboration that define Duravant.”
“Looking ahead, I am delighted that Jill will succeed me as CEO,” said Mr. Kachmer. Her extensive experience, demonstrated capabilities, and winning spirit make her the perfect person to lead Duravant forward. I am confident that Jill and her leadership team will continue to build on our strong foundation and take Duravant to new heights.”
About Duravant
Duravant is a global leader in advanced automation solutions operating across the food processing, packaging, and material handling industries. Founded on more than a century of expertise, Duravant delivers performance-driven technologies, integrated systems and full lifecycle services that drive productivity, efficiency and safety for the world’s producers and movers of high demand goods. The company serves a broad range of essential end markets including food & beverage, agriculture, consumer and industrial goods, e-commerce, and logistics. Headquartered in Downers Grove, Illinois, and serving customers in more than 190 countries, Duravant unites a portfolio of leading brands under a shared commitment to quality, innovation and customer success. For more information, visit www.duravant.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117036720/en/
Contacts
Duravant Media Contact:
Eleni Yianas
Sr. Vice President, Marketing
Eleni.yianas@duravant.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press Release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press Release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press Release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom